121 related articles for article (PubMed ID: 8935750)
21. A high level of carcinoembryonic antigen as initial manifestation of medullary thyroid carcinoma in a patient with subclinical hyperthyroidism.
Akbulut S; Sogutcu N
Int Surg; 2011; 96(3):254-9. PubMed ID: 22216705
[TBL] [Abstract][Full Text] [Related]
22. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
23. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma].
Hao WJ; Zhang H; Yu Y; Zhao J; Ge ZJ; Ding PX; Sun XX; Liu H; Wen SY; You J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 54(7):506-509. PubMed ID: 31315357
[No Abstract] [Full Text] [Related]
25. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
26. [Medullary thyroid carcinoma].
De Medici A; Zucchermaglio MT; Mottola P; Cebrelli CF
Minerva Chir; 1999 May; 54(5):343-54. PubMed ID: 10443116
[TBL] [Abstract][Full Text] [Related]
27. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
29. Biochemical markers in the follow-up of medullary thyroid cancer.
de Groot JW; Kema IP; Breukelman H; van der Veer E; Wiggers T; Plukker JT; Wolffenbuttel BH; Links TP
Thyroid; 2006 Nov; 16(11):1163-70. PubMed ID: 17123344
[TBL] [Abstract][Full Text] [Related]
30. Need for revision of diagnostic limits for medullary thyroid carcinoma with a new immunochemiluminometric calcitonin assay.
Ramachandran R; Benfield P; Dhillo WS; White S; Chapman R; Meeran K; Donaldson M; Martin NM
Clin Chem; 2009 Dec; 55(12):2225-6. PubMed ID: 19833839
[No Abstract] [Full Text] [Related]
31. Calcitonin-like polypeptides without apparent biological activity in a patient with recurrent medullary thyroid carcinoma.
Nakajima K; Jinkawa I; Hirota T; Ikeda T; Tugawa M; Minami Y; Hanada M
Intern Med; 1995 Sep; 34(9):896-900. PubMed ID: 8580565
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia.
Faggiano A; Talbot M; Lacroix L; Bidart JM; Baudin E; Schlumberger M; Caillou B
Clin Endocrinol (Oxf); 2002 Dec; 57(6):813-9. PubMed ID: 12460332
[TBL] [Abstract][Full Text] [Related]
33. Thyroid medullary carcinoma in a teenager with Cowden syndrome.
Koksal Y; Sahin M; Koksal H; Orhan D; Unal E; Alagoz E
Laryngoscope; 2007 Jul; 117(7):1180-2. PubMed ID: 17603316
[TBL] [Abstract][Full Text] [Related]
34. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
[TBL] [Abstract][Full Text] [Related]
35. Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma.
Ide A; Ashizawa K; Ishikawa N; Ishii R; Ando T; Abe Y; Sera N; Usa T; Tominaga T; Ejima E; Nakashima M; Ito K; Ito K; Eguchi K
Thyroid; 2001 Nov; 11(11):1055-61. PubMed ID: 11762716
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease.
Herrmann BL; Schmid KW; Goerges R; Kemen M; Mann K
Eur J Endocrinol; 2010 Jun; 162(6):1141-5. PubMed ID: 20332126
[TBL] [Abstract][Full Text] [Related]
37. Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions.
Komminoth P; Roth J; Saremaslani P; Matias-Guiu X; Wolfe HJ; Heitz PU
Am J Surg Pathol; 1994 Apr; 18(4):399-411. PubMed ID: 8141431
[TBL] [Abstract][Full Text] [Related]
38. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
40. Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level.
Gill S; Cosolo W; Herbertson RA; Berlangieri SU; Scott AM
Intern Med J; 2009 Apr; 39(4):264-5. PubMed ID: 19220550
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
